In the DMD trial (IGNITE), treatment of a boy with a high dose (2x1014 vg/kg) of the therapeutic vector (SGT-001, encoding micro-dystrophin) resulted in lower red blood cell and platelet counts (thrombocytopenia), caused kidney damage, and activated the complement system. Here, DMD is linked to Duchenne muscular dystrophy.